NL-OMON39774已完成不适用
Prostate Cancer Molecular Medicine - PCMM
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 496
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •planned to undergo prostate biopsies according to standard practice
- •signed informed consent;Group 2:
- •cT1-3Nx-0Mx-0 prostate cancer
- •scheduled for radical prostatectomy according to standard practice
- •signed informed consent
排除标准
- •Group 2 only:
- •known allergy to contrast agents or sulphur hexafluoride micro bubbles
- •documented acute prostatitis or urinary tract infections within 8 weeks prior to inclusion
- •severe cardiac condition
- •any clinically unstable cardiac condition within 7 days prior to contrast agent administration such
- •- evolving or ongoing myocardial infarction
- •- typical angina at rest
- •- significant worsening of cardiac symptoms
- •- recent coronary artery intervention or other factors suggesting clinical instability (e.g., recent
- •deterioration of ECG, laboratory or clinical findings)
- •- acute cardiac failure, class III/IV cardiac failure
- •- severe cardiac rhythm disorders
- •- right-to-left shunts
- •known severe pulmonary hypertension (pulmonary artery pressure >90 mmHg) or uncontrolled
- •systemic hypertension or respiratory distress syndrome
- •renal insufficiency (GFR < 30 ml/min)
- •vulnerable for epilepsy
- •presence of a pacemaker or other implants or clamps
研究者
相似试验
招募中
不适用
Prostate Cancer Molecular Medicine (PCMM).Prostate cancer / prostaatkankerNL-OMON27495Erasmus MC, NKI-AvL, UMCG, UMC400
已完成
不适用
Prostate Cancer Molecular Medicine: Transition Grant 2015 (ProCaMolMed)Prostate cancerNL-OMON42675Erasmus MC, Universitair Medisch Centrum Rotterdam525
进行中（未招募）
1 期
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Metastatic prostate cancerEUCTR2022-003788-13-FIHeikki Minn40
进行中（未招募）
1 期
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Prostate cancerCTIS2024-511104-16-00Turku University Hospital40
招募中
1 期
Molecular epidemiological analysis of prostate cancer in Hunan populatioprostate cancerITMCTR2200005999the First Affiliated Hospital of Hunan University of Chinese Medicine